LucasBio is devoted to constantly moving
forward to develop new biomedical drugs for incurable diseases.
2024.07
- Ministry of Food and Drug Safety Clinical Trial Approval: No. 102261
'Single-center, open-label, phase 1 clinical trial to evaluate the safety, tolerability, and efficacy of a single dose of LB-DTK-COV19 in patients with severe COVID-19'
2024.07
- Approval of designation by Korean FDA as Good Clinical Laboratory Practice Central Lab
2023.05
- Selected as a research project for the Korea Health Industry Development Institute infectious disease prevention and treatment technology development project
'Research on the development of SARS coronavirus-2 antigen-specific T cell therapy for the treatment of new and variant COVID-19'
2023.04
- Selected as a research project for the regenerative medicine linked technology development project by the pan-governmental regenerative medicine technology development project group
''Safety, effectiveness evaluation and commercialization research of placental decidua stromal cell therapy to overcome inflammatory bowel disease'
2023.02
- Approval for advanced regenerative medicine medium-risk clinical study: autologous COVID-19-specific T cells
'Clinical study to evaluate the safety and effectiveness of autologous COVID-19 antigen-specific T cell therapy for patients infected with SARS-Coronavirus-2 for a long period of time'
2023.01
- Selected as a research project for the National Research Foundation of Korea market-linked biotechnology development project
'Research to establish the concept of placental decidua-derived stromal cells and secure treatment for intractable complications that occur after allogeneic hematopoietic stem cell transplantation'
2022.06
- Selected as a research project for the Korea Health Industry Development Institute’s Regenerative Medicine Clinical Research Foundation Creation Project
'Establishment of a hospital-based cell therapy consignment development and production system'
2021.12
- Approved for advanced regenerative medicine medium-risk clinical study: autologous cytokine-induced killer cells
'Researcher-led clinical study to evaluate the safety of cytokine-induced killer cell administration in the early stages of transplantation in autologous hematopoietic stem cell transplant patients'
2020.10
- Received venture certificate - Korea SME's and Startups Agency
2020.07
- Established Lucasbio's R&D Lab
2020.03
- Japanese Patent Registration: Method for inducing and proliferating viral antigen-specific T cells
(No. 2018-521069)
2019.11
- Completed Phase I investigator-initiated clinical trial using bone-marow derived mesenchymal stem cells for chronic graft-versus-host disease
(CRIS registration No. KCT001894)
2019.07
- Establishment of LucasBio Co., Ltd.
2018.06
- Korean Patent Registration: Method for inducing and proliferating viral antigen-specific T cells
(No. 10-1867942)
